{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:25:13Z","timestamp":1792707913293,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11926-022-01069-3","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T13:02:38Z","timestamp":1649941358000},"page":"132-138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Update on Uric Acid and the Kidney"],"prefix":"10.1007","volume":"24","author":[{"given":"Giana Kristy","family":"Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"issue":"6","key":"1069_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1053\/j.ackd.2012.07.014","volume":"19","author":"TH Mehta","year":"2012","unstructured":"Mehta TH, Goldfarb DS. Uric acid stones and hyperuricosuria. Adv Chronic Kidney Dis. 2012;19(6):413\u20138.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"11","key":"1069_CR2","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/rheumatology\/keq204","volume":"49","author":"B Alvarez-Lario","year":"2010","unstructured":"Alvarez-Lario B, Macarron-Vicente J. Uric acid and evolution. Rheumatology (Oxford). 2010;49(11):2010\u20135.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"1069_CR3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/01.mnh.0000232876.04975.33","volume":"15","author":"OW Moe","year":"2006","unstructured":"Moe OW. Uric acid nephrolithiasis: proton titration of an essential molecule? Curr Opin Nephrol Hypertens. 2006;15(4):366\u201373.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"8","key":"1069_CR4","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1002\/art.41749","volume":"73","author":"AL Gaffo","year":"2021","unstructured":"Gaffo AL, Calhoun DA, Rahn EJ, Oparil S, Li P, Dudenbostel T, et al. Effect of serum urate lowering with allopurinol on blood pressure in young adults: a randomized, controlled, crossover trial. Arthritis Rheumatol. 2021;73(8):1514\u201322.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1069_CR5","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1001\/jama.300.8.924","volume":"300","author":"DI Feig","year":"2008","unstructured":"Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008;300(8):924\u201332.","journal-title":"JAMA"},{"issue":"1","key":"1069_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1161\/HYPERTENSIONAHA.119.12727","volume":"74","author":"RJ Johnson","year":"2019","unstructured":"Johnson RJ, Choi HK, Yeo AE, Lipsky PE. Pegloticase treatment significantly decreases blood pressure in patients with chronic gout. Hypertension. 2019;74(1):95\u2013101.","journal-title":"Hypertension"},{"issue":"2","key":"1069_CR7","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3233\/JPD-181535","volume":"9","author":"I Sleeman","year":"2019","unstructured":"Sleeman I, Lawson RA, Yarnall AJ, Duncan GW, Johnston F, Khoo TK, et al. Urate and homocysteine: predicting motor and cognitive changes in newly diagnosed Parkinson\u2019s disease. J Parkinsons Dis. 2019;9(2):351\u20139.","journal-title":"J Parkinsons Dis"},{"issue":"10","key":"1069_CR8","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/jama.2021.10207","volume":"326","author":"MA Schwarzschild","year":"2021","unstructured":"Parkinson Study Group S-PDI, Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC, Fitzgerald R, et al. Effect of urate-elevating inosine on early Parkinson disease progression: the SURE-PD3 randomized clinical trial. JAMA. 2021;326(10):926\u201339.","journal-title":"JAMA"},{"issue":"1\u20132","key":"1069_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/21678421.2016.1214733","volume":"18","author":"EJ O'Reilly","year":"2017","unstructured":"O\u2019Reilly EJ, Liu D, Johns DR, Cudkowicz ME, Paganoni S, Schwarzschild MA, et al. Serum urate at trial entry and ALS progression in EMPOWER. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(1\u20132):120\u20135.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"1069_CR10","doi-asserted-by":"publisher","first-page":"602663","DOI":"10.3389\/fneur.2021.602663","volume":"12","author":"LQ Xu","year":"2021","unstructured":"Xu LQ, Hu W, Guo QF, Xu GR, Wang N, Zhang QJ. Serum uric acid levels predict mortality risk in male amyotrophic lateral sclerosis patients. Front Neurol. 2021;12:602663.","journal-title":"Front Neurol."},{"issue":"2","key":"1069_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/j.1523-1755.2004.00386.x","volume":"65","author":"N Abate","year":"2004","unstructured":"Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004;65(2):386\u201392.","journal-title":"Kidney Int"},{"issue":"7","key":"1069_CR12","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2215\/CJN.08331109","volume":"5","author":"NM Maalouf","year":"2010","unstructured":"Maalouf NM, Cameron MA, Moe OW, Sakhaee K. Metabolic basis for low urine pH in type 2 diabetes. Clin J Am Soc Nephrol. 2010;5(7):1277\u201381.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1069_CR13","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.kint.2018.11.024","volume":"95","author":"NM Maalouf","year":"2019","unstructured":"Maalouf NM, Poindexter JR, Adams-Huet B, Moe OW, Sakhaee K. Increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone. Kidney Int. 2019;95(5):1262\u20138.","journal-title":"Kidney Int"},{"issue":"5","key":"1069_CR14","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.kint.2019.02.003","volume":"95","author":"JR Asplin","year":"2019","unstructured":"Asplin JR, Goldfarb DS. Effect of thiazolidinedione therapy on the risk of uric acid stones. Kidney Int. 2019;95(5):1022\u20134.","journal-title":"Kidney Int"},{"issue":"3","key":"1069_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2215\/CJN.10420818","volume":"14","author":"IA Bobulescu","year":"2019","unstructured":"Bobulescu IA, Park SK, Xu LHR, Blanco F, Poindexter J, Adams-Huet B, et al. Net acid excretion and urinary organic anions in idiopathic uric acid nephrolithiasis. Clin J Am Soc Nephrol. 2019;14(3):411\u201320.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"1069_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1053\/j.ajkd.2017.01.053","volume":"70","author":"S Kim","year":"2017","unstructured":"Kim S, Chang Y, Yun KE, Jung HS, Lee SJ, Shin H, et al. Development of nephrolithiasis in asymptomatic hyperuricemia: a cohort study. Am J Kidney Dis. 2017;70(2):173\u201381.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"1069_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1053\/j.ajkd.2020.11.018","volume":"78","author":"RK Narang","year":"2021","unstructured":"Narang RK, Gamble GG, Topless R, Cadzow M, Stamp LK, Merriman TR, et al. Assessing the relationship between serum urate and urolithiasis using Mendelian randomization: an analysis of the UK Biobank. Am J Kidney Dis. 2021;78(2):210\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1069_CR18","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1046\/j.1523-1755.2003.t01-2-00171.x","volume":"64","author":"HJ Kramer","year":"2003","unstructured":"Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolithiasis in men: the health professionals\u2019 follow-up study. Kidney Int. 2003;64(3):1022\u20136.","journal-title":"Kidney Int"},{"issue":"7","key":"1069_CR19","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1681\/ASN.2006030262","volume":"17","author":"M Daudon","year":"2006","unstructured":"Daudon M, Traxer O, Conort P, Lacour B, Jungers P. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol. 2006;17(7):2026\u201333.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"1069_CR20","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3899\/jrheum.101156","volume":"38","author":"DS Goldfarb","year":"2011","unstructured":"Goldfarb DS, MacDonald PA, Hunt B, Gunawardhana L. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. J Rheumatol. 2011;38(7):1385\u20139.","journal-title":"J Rheumatol"},{"issue":"3","key":"1069_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1074-5521(03)00057-7","volume":"10","author":"PK Grover","year":"2003","unstructured":"Grover PK, Marshall VR, Ryall RL. Dissolved urate salts out calcium oxalate in undiluted human urine in vitro: implications for calcium oxalate stone genesis. Chem Biol. 2003;10(3):271\u20138.","journal-title":"Chem Biol"},{"issue":"22","key":"1069_CR22","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1056\/NEJM198611273152204","volume":"315","author":"B Ettinger","year":"1986","unstructured":"Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315(22):1386\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"1069_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/sj.ki.5002708","volume":"73","author":"GC Curhan","year":"2008","unstructured":"Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008;73(4):489\u201396.","journal-title":"Kidney Int"},{"issue":"2","key":"1069_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1053\/j.ajkd.2017.05.004","volume":"70","author":"PM Ferraro","year":"2017","unstructured":"Ferraro PM, Curhan GC. Serum uric acid and risk of kidney stones. Am J Kidney Dis. 2017;70(2):158\u20139.","journal-title":"Am J Kidney Dis"},{"key":"1069_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1475-2891-9-45","volume":"9","author":"A Kanbara","year":"2010","unstructured":"Kanbara A, Hakoda M, Seyama I. Urine alkalization facilitates uric acid excretion. Nutr J. 2010;9:45.","journal-title":"Nutr J"},{"issue":"2","key":"1069_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11926-010-0089-y","volume":"12","author":"JE Kenny","year":"2010","unstructured":"Kenny JE, Goldfarb DS. Update on the pathophysiology and management of uric acid renal stones. Curr Rheumatol Rep. 2010;12(2):125\u20139.","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"1069_CR27","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, et al. American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744\u201360.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"1069_CR28","first-page":"34","volume":"18","author":"M Yunhua","year":"2020","unstructured":"Yunhua M, Hao Z, Ke L, Wentao H, Xiaokang L, Jie S. Febuxostat promoted dissolution of radiolucent nephrolithiasis in patients with hyperuricemia. Urol J. 2020;18(1):34\u20139.","journal-title":"Urol J"},{"issue":"10\u201311","key":"1069_CR29","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1159\/000519491","volume":"52","author":"A Goldberg","year":"2021","unstructured":"Goldberg A, Garcia-Arroyo F, Sasai F, Rodriguez-Iturbe B, Sanchez-Lozada LG, Lanaspa MA, et al. Mini review: reappraisal of uric acid in chronic kidney disease. Am J Nephrol. 2021;52(10\u201311):837\u201344.","journal-title":"Am J Nephrol"},{"key":"1069_CR30","first-page":"5817348","volume":"2020","author":"HY Su","year":"2020","unstructured":"Su HY, Yang C, Liang D, Liu HF. Research advances in the mechanisms of hyperuricemia-induced renal injury. Biomed Res Int. 2020;2020:5817348.","journal-title":"Biomed Res Int"},{"issue":"6","key":"1069_CR31","doi-asserted-by":"publisher","first-page":"F1327","DOI":"10.1152\/ajprenal.00272.2019","volume":"318","author":"SW Jung","year":"2020","unstructured":"Jung SW, Kim SM, Kim YG, Lee SH, Moon JY. Uric acid and inflammation in kidney disease. Am J Physiol Renal Physiol. 2020;318(6):F1327\u201340.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1069_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","volume":"17","author":"MJ Roughley","year":"2015","unstructured":"Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17:90.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"1069_CR33","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.kint.2020.08.024","volume":"99","author":"T Bardin","year":"2021","unstructured":"Bardin T, Nguyen QD, Tran KM, Le NH, Do MD, Richette P, et al. A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int. 2021;99(1):218\u201326.","journal-title":"Kidney Int"},{"issue":"8","key":"1069_CR34","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"M Goicoechea","year":"2010","unstructured":"Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388\u201393.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"26","key":"1069_CR35","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMoa1916624","volume":"382","author":"A Doria","year":"2020","unstructured":"Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020;382(26):2493\u2013503.","journal-title":"N Engl J Med"},{"issue":"26","key":"1069_CR36","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","volume":"382","author":"SV Badve","year":"2020","unstructured":"Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504\u201313.","journal-title":"N Engl J Med"},{"issue":"3","key":"1069_CR37","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10067-021-05956-5","volume":"41","author":"S Tsukamoto","year":"2021","unstructured":"Tsukamoto S, Okami N, Yamada T, Azushima K, Yamaji T, Kinguchi S, et al. Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis. Clin Rheumatol. 2021;41(3):911\u20139.","journal-title":"Clin Rheumatol"},{"key":"1069_CR38","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;(3):1\u2013150."},{"key":"1069_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cct.2018.03.015","volume":"68","author":"S Timilsina","year":"2018","unstructured":"Timilsina S, Brittan K, O\u2019Dell JR, Brophy M, Davis-Karim A, Henrie AM, et al. Design and rationale for the Veterans Affairs \u201cCooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat\u201d trial. Contemp Clin Trials. 2018;68:102\u20138.","journal-title":"Contemp Clin Trials."},{"issue":"10","key":"1069_CR40","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41584-021-00657-4","volume":"17","author":"LK Stamp","year":"2021","unstructured":"Stamp LK, Farquhar H, Pisaniello HL, Vargas-Santos AB, Fisher M, Mount DB, et al. Management of gout in chronic kidney disease: a G-CAN consensus statement on the research priorities. Nat Rev Rheumatol. 2021;17(10):633\u201341.","journal-title":"Nat Rev Rheumatol"},{"issue":"13","key":"1069_CR41","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200\u201310.","journal-title":"N Engl J Med"},{"issue":"2","key":"1069_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","volume":"51","author":"RT Keenan","year":"2021","unstructured":"Keenan RT, Botson JK, Masri KR, Padnick-Silver L, LaMoreaux B, Albert JA, et al. The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review. Semin Arthritis Rheum. 2021;51(2):347\u201352.","journal-title":"Semin Arthritis Rheum"},{"key":"1069_CR43","doi-asserted-by":"publisher","unstructured":"O\u2019Dell JR, Brophy MT, Pillinger MH, Neogi T, Palevsky PM, Wu H, et al. Comparative effectiveness of allopurinol and febuxostat in gout management. NEJM Evid 2022;1(3). https:\/\/doi.org\/10.1056\/EVIDoa2100028","DOI":"10.1056\/EVIDoa2100028"},{"key":"1069_CR44","doi-asserted-by":"crossref","unstructured":"Khanna P, Johnson RJ, Marder B, LaMoreaux B, Kumar A. Systemic urate deposition: an unrecognized complication of gout? J Clin Med. 2020;9(10):3204.","DOI":"10.3390\/jcm9103204"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-022-01069-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-022-01069-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-022-01069-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T06:41:33Z","timestamp":1651732893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-022-01069-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1069"],"URL":"https:\/\/doi.org\/10.1007\/s11926-022-01069-3","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]},"assertion":[{"value":"21 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ramos: none; Goldfarb: owner: Moonstone Inc; consultant: Allena, Alnylam, AstraZeneca, Cymabay, Dicerna, Synlogic; research: Travere.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}